All sponsors

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. $1177.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-35
RECRUITING6
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO20%

Delay Index: of 5 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. on the live radar map → 📅 $1177.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection
NCT06854445
P2RecruitingDiffuse Large Cell B-lymphoma552025-10
TQH2722 injection
NCT07398859
P2RecruitingSeasonal Allergic Rhinitis3002026-11
TQC2731 injection
NCT06707883
P2Active, not recruitingChronic Obstructive Pulmonary Disease2582026-12
TQC2731 injection
NCT07107256
P3Active, not recruitingChronic Rhinosinusitis With Nasal Polyps (CRSwNP)2462027-03
Kylo 0603 Capsule 8mg
NCT07878091
P2Not yet recruitingMetabolic Dysfunction-Associated Steatoic Liver Disease1202027-08-15
TQB2922 injection (subcutaneous administration)
NCT07844187
P1/2Not yet recruitingColorectal Neoplasms642027-08-31
TQC2731 injection
NCT06829784
P3RecruitingAsthma6602027-12 (+6 mo)
TQB2868 Injection
NCT07165951
P3RecruitingMetastatic Pancreatic Ductal Adenocarcinoma5662028-05
TQB2825 Injection
NCT07187960
P3Not yet recruitingFollicular Lymphoma2282028-10
LM-302 Injection
NCT07385703
P3RecruitingAdenocarcinoma7522028-10
TQB2922 Subcutaneous Injection
NCT07601204
P1/2Not yet recruitingRecurrent/Metastatic Head and Neck Cancer1282029-02
TQB2934 injection
NCT07266116
P1/2RecruitingSystemic Light Chain Amyloidosis702029-02